BioHarvest Sciences (NASDAQ:BHST) Stock Price Down 5.5% – Here’s Why

Shares of BioHarvest Sciences Inc. (NASDAQ:BHST) fell 5.5% during mid-day trading on Thursday . The stock traded as low as $2.75 and last traded at $2.75. Approximately 36,352 shares traded hands during mid-day trading, an increase of 61% from the average session volume of 22,582 shares. The stock had previously closed at $2.91.

Analysts Set New Price Targets

Separately, Weiss Ratings upgraded BioHarvest Sciences from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, June 18th. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $10.00.

BioHarvest Sciences Trading Down 5.5%

The company has a market cap of $53.95 million, a PE ratio of -4.66 and a beta of 0.70. The stock’s 50 day moving average is $3.76 and its 200-day moving average is $4.45. The company has a quick ratio of 2.44, a current ratio of 2.96 and a debt-to-equity ratio of 0.03.

BioHarvest Sciences (NASDAQ:BHST) last issued its quarterly earnings data on Thursday, May 14th. The company reported ($0.11) EPS for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.02. BioHarvest Sciences had a negative net margin of 32.54% and a negative return on equity of 76.03%. The business had revenue of $8.51 million during the quarter, compared to analysts’ expectations of $8.50 million. As a group, sell-side analysts anticipate that BioHarvest Sciences Inc. will post -0.45 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Virtu Financial LLC bought a new stake in BioHarvest Sciences during the fourth quarter worth approximately $60,000. Geode Capital Management LLC bought a new stake in shares of BioHarvest Sciences in the 4th quarter valued at approximately $61,000. HRT Financial LP purchased a new position in shares of BioHarvest Sciences in the 4th quarter worth approximately $75,000. Marshall Wace LLP purchased a new stake in BioHarvest Sciences during the 4th quarter valued at $110,000. Finally, Silverberg Bernstein Capital Management LLC purchased a new stake in BioHarvest Sciences during the 1st quarter valued at $113,000.

BioHarvest Sciences Company Profile

BioHarvest Sciences Inc is a biotechnology company that specializes in the development and commercialization of plant-based active ingredients through proprietary cell-culture technology. By growing undifferentiated plant cells in controlled bioreactor environments, the company aims to produce full-spectrum phytonutrients and botanical compounds that are difficult to obtain through traditional farming methods. This approach is designed to deliver consistent, high-purity extracts with reduced environmental impact and supply-chain variability.

The company’s product portfolio focuses on applications across the cosmeceutical, nutraceutical and health-and-wellness markets.